Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dasatinib - Nanocopoeia

Next Previous
X
Search
Drug Profile

Dasatinib - Nanocopoeia

Alternative Names: PHYRAGO

Latest Information Update: 02 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nanocopoeia
  • Class Amides; Antineoplastics; Chlorobenzenes; Piperazines; Pyrimidines; Small molecules; Thiazoles
  • Mechanism of Action Bcr-Abl tyrosine kinase inhibitors; EphA2 receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto-oncogene protein c-kit inhibitors; Src-family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 11 Oct 2023 Nanocopoeia resubmits NDA for treatment of patients with Chronic myeloid leukaemia (In adults, First-line therapy, Second-line therapy or greater) and Precursor cell lymphoblastic leukaemia-lymphoma (Second-line therapy or greater, In adults) in USA (PO)
  • 12 May 2023 Registered for Chronic myeloid leukaemia (First-line therapy, In adults) in USA (PO)
  • 12 May 2023 Registered for Chronic myeloid leukaemia (Second-line therapy or greater, In adults) in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top